



MAPS

Bulletin of the Multidisciplinary Association for Psychedelic Studies

-
- 3 Letter from the President**
Rick Doblin
-
- 4 Forty Year Follow-Up to Dr. Oscar Janiger's Pioneering LSD Research**
Rick Doblin, Jerry Beck, Ph.D., Kate Obata and Maureen Alioto
Introduction by Dr. Oscar Janiger
-
- 22 The Imprint of an LSD Experiment, Forty Years Later**
Kate Obata
-
- 23 Persistence of Memory: Recollections of Participation in an LSD Study**
Maureen Alioto
-
- 24 Sacred Work in a Secular World:
Guided, Structured, Group Use of Entheogens**
Roger Marsden
-
- 30 A Biochemical Bridge to Embodied Psyche:
LSD Research 1945-1965**
Kim Hewitt
-
- 35 The Second Generation Project: Families who value psychedelics**
Adele Getty-Huxley
-
- 36 Planning a Salvia with Meditation Study**
Ian Soutar
-
- 37 Ecstasy Harm Reduction Project**
Emanuel Sferios
-
- 39 Ketamine Psychedelic Therapy: Two Reports**
Evgeny M. Krupitsky, MD, Ph.D., et al.
-
- 42 Clinical MDMA Research Update**
Matthew Baggott
-
- 43 Heffter Research Institute Update**
David Nichols, Ph.D.
-
- 45 The Hofmann Report**
Myron Stolaroff, M.S.
-
- 46 Non-Anglo Entheography: Mini-Reviews of Non-English Publications, IV**
Jonathan Ott
-

- 51 The Literature of Psychedelics**
Bob Wallace
-
- 53 Conference and Seminar Updates**
Entheobotany 1999, Ayahuasca and Holotropic Breathwork, Telluride Conference
-
- 54 Readers' Forum**
-
- 56 Readers' Forum Highlight: MDMA and cancer**
-
- 59 Announcements**
-
- 60 MAPS Membership and Renewal Information**
-

ISSN 1080-8981

MAPS (Multidisciplinary Association for Psychedelic Studies) is a membership-based organization working to assist psychedelic researchers around the world design, obtain governmental approval, fund, conduct and report on psychedelic research in humans. Founded in 1986, MAPS is an IRS approved 501 (c)(3) non-profit corporation funded by tax deductible donations. MAPS has previously funded basic scientific research into the safety of MDMA (3,4, methylenedioxymethamphetamine, Ecstasy) and has opened a Drug Master File for MDMA at the U.S. Food and Drug Administration. MAPS is now focused primarily on assisting scientists to conduct human studies to generate essential information about the risks and psychotherapeutic benefits of MDMA, other psychedelics, and marijuana, with the goal of eventually gaining government approval for their medical uses. Interested parties wishing to copy any portion of this Bulletin are encouraged to do so and are kindly requested to credit MAPS including name and address. The MAPS Bulletin is produced by a small group of dedicated staff and volunteers. Your participation, financial or otherwise, is welcome.

© 1999 Multidisciplinary Association for Psychedelic Studies, Inc. (MAPS)
2105 Robinson Avenue, Sarasota, Florida 34232 USA.
Phone: 941/924-MAPS (6277). Fax 941/924-6265.
Internet: info@maps.org and <http://www.maps.org>